Triple drug combo aims to reverse heart scarring in stiff heart failure

NCT ID NCT06655480

Recruiting now Disease control Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a three-drug combination (SGLT2 inhibitor, ARNI, and MRA) can improve heart structure, function, and symptoms in 50 people with advanced HFpEF, a type of heart failure where the heart is stiff but pumps normally. Participants will receive either the triple therapy or standard care for 52 weeks. The goal is to see if the combination reduces heart scarring and improves exercise ability and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYOCARDIAL FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure endomyocardial fibrosis Hypertrophy, Left Ventricular

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HFPEF LVDD MYOCARDIAL FIBROSIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
RECRUITING

Moscow, Russia

Contact Phone: •••-•••-•••• Email: •••••@•••••